Ashkon Software

   







 


ACHN - Achillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals, Inc. logo Achillion Pharmaceuticals, Inc. (ACHN) is a clinical-stage biopharmaceutical company that is focused on the development of small molecule drugs to treat immune system disorders and viral infections, including hepatitis C.

Achillion Pharmaceuticals is primarily focused on the development of oral small molecule drugs for the treatment of immune system disorders and viral infections. The company's lead drug candidate is danicopan (ACH-4471), which is being developed for the treatment of complement-mediated diseases.

In addition, the company has a pipeline of drug candidates for the treatment of viral infections, including hepatitis C. Achillion Pharmaceuticals has previously developed several drugs for the treatment of hepatitis C, including sovaprevir and odalasvir, which were later licensed to other companies.

The company has reported financial results for the third quarter of 2021, reporting a net loss of $15.2 million, compared to a net loss of $19.4 million in the same period in the previous year. Achillion Pharmaceuticals reported cash, cash equivalents, and marketable securities of $254.5 million as of September 30, 2021.

Achillion Pharmaceuticals has been focused on advancing its pipeline of drug candidates and entering into partnerships and collaborations with other companies. In October 2021, the company announced that it had entered into a strategic collaboration with Pandion Therapeutics to develop novel immune modulators for the treatment of autoimmune and inflammatory diseases.

However, the company's financial performance and operations may be impacted by various factors, including the outcome of clinical trials, regulatory changes, and competition in the biopharmaceutical industry. In addition, the ongoing COVID-19 pandemic may continue to cause disruptions in the global economy and the healthcare industry, which may affect Achillion Pharmaceuticals' operations and financial results.

Overall, Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of small molecule drugs to treat immune system disorders and viral infections. The company has a pipeline of drug candidates and has entered into partnerships and collaborations to advance its research and development efforts. However, the company's financial performance and operations are subject to various risks and uncertainties associated with the biopharmaceutica

 



 

 

 
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer